Author

Masaya Tanahashi

Observed name: M Tanahashi

Institution: Kowa (Japan)

Observed institution: Kowa (Japan)

ORCID: 0009-0004-3648-4075

Observed ORCID: 0009-0004-3648-4075

OpenAlex ID: A5029566055

Effects of Pemafibrate on LDL-C and Related Lipid Markers in Patients with MASLD: A Sub-Analysis of the PEMA-FL Study

2024 · Ryohei Tanigawa, Atsushi Nakajima, et al. · Journal of Atherosclerosis and Thrombosis · 11

Pitavastatin therapy in polymedicated patients is associated with a low risk of drug-drug interactions: analysis of real-world and phase 3 clinical trial data

2015 · Masahiko Gosho, Masaya Tanahashi, et al. · International Journal of Clinical Pharmacology and Therapeutics · 9

Post Hoc Analysis of a Phase 2 Randomized Trial of Pemafibrate in Metabolic Dysfunction–associated Steatotic Liver Disease: Associations With Platelet Count, Liver Stiffness, and Spleen Volume

2026 · Ryohei Tanigawa, Rohit Loomba, et al. · Journal of Clinical and Experimental Hepatology · 5

Pitavastatin 4 mg vs. Pravastatin 40 mg in HIV Dyslipidemia: Post-Hoc Analysis of the INTREPID Trial Based on the Independent CHD Risk Factor of Age†

2014 · Craig A. Sponseller, Masaya Tanahashi, et al. · Journal of clinical lipidology · 4

Efficacy for LDL-C–lowering and safety of pemafibrate extended-release formulation in patients with statin-intolerant hypercholesterolemia: A phase 3 multicenter, randomized, double-blind, placebo-controlled, parallel-group trial

2026 · Shizuya Yamashita, Eiichi Araki, et al. · Journal of clinical lipidology · 3

Effects of Pemafibrate on Serum Carnitine and Plasma Myostatin in Patients With Metabolic Dysfunction Associated Steatotic Liver Disease

2025 · Ryohei Tanigawa, Atsushi Nakajima, et al. · JCSM Communications · 3

Post‐hoc analysis of the tofogliflozin post‐marketing surveillance study (J‐ STEP / LT ): Tofogliflozin improves liver function in type 2 diabetes patients regardless of BMI

2025 · Hiroyuki Uchinuma, Mitsunori Matsushita, et al. · Journal of Diabetes Investigation · 2

Corrigendum to “Post Hoc Analysis of a Phase 2 Randomized Trial of Pemafibrate in Metabolic Dysfunction–associated Steatotic Liver Disease: Associations With Platelet Count, Liver Stiffness, and Spleen Volume” [J Clin Exp Hepatol 16 (4) (2026) 103525]

2026 · Ryohei Tanigawa, Rohit Loomba, et al. · Journal of Clinical and Experimental Hepatology

Post Hoc Subgroup Analysis by Disease Severity in a Non-Inferiority Trial of Donepezil 27.5 mg Transdermal Formulation in Japanese Patients With Mild-to-Moderate Alzheimer Disease

2026 · Yu Nakamura, Takuma Tsushio, et al. · Alzheimer Disease & Associated Disorders

Efficacy and safety of pemafibrate in patients with statin-intolerant hypercholesterolemia: results from a 12-week, randomized, double blind, placebo-controlled, phase 3 trial

2025 · S Yamashita, H Arai, et al. · European Heart Journal

Risk of Venous Thromboembolism with Pemafibrate in Dyslipidemia: A Nationwide, Retrospective, Cohort Study Using a Japanese Claims Database

2025 · Kenichiro Ikeda, Mika Tada, et al. · Therapeutic Innovation & Regulatory Science

Works count: 11

Citation count: 37

H-index: 4

I10-index: 1